Abstract:BACKGROUND: Certain herbal medicines have been reported to be effective in the treatment of psychiatric conditions, and combination treatment with drugs and herbal medicines has been reported to be useful in enhancing treatment efficacy and reducing recovery time and adverse events (AEs).OBJECTIVE: The purpose of this study was to investigate the effectiveness and tolerability of warm-supplementing kidney yang (WSKY) added to risperidone in improving cognitive impairment and negative symptoms (ie, cognitive function) in patients with schizophrenia.METHODS: This 8-week, multicenter, randomized, double-blind, placebo-controlled clinical trial was conducted in patients who met the clinical classification for schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Patients were recruited from 3 centers (including inpatient and outpatient clinics) and were evenly randomized to receive WSKY or placebo added to risperidone for 8 weeks. Primary assessments were conducted at weeks 2, 4, and 8. A clinical response was defined as a >= 50% reduction score (from baseline) on the Positive and Negative Syndrome Scale (PANSS), a >= 30% reduction score (from baseline) on the Scale for the Assessment of Negative Symptoms (SANS), or a > 50% reduction score (from baseline) on the Hamilton Rating Scale for Depression (HAM-D-17). Cognitive function was assessed using the Wisconsin Card Sorting Test (WCST) at baseline and end point. Extrapyramidal AEs were assessed weekly using the Abnormal Involuntary Movement Scale (AIMS) and the Rating Scale for Extrapyramidal Side Effects (RSESE). AEs were assessed by patient interviews conducted at each clinic visit and also by the Treatment Emergent Symptoms Scale (TESS) scores.RESULTS: One-hundred twenty patients (62 males, 58 females; mean [SD] age, 34.4 [9.4] years; range, 18-45 years; baseline mean [SD] PANSS score, 88.7 [12.3]) were included in this study. Risperidone- and WSKY-treated patients had statistically significant improvements at end point in the number of completed categories (P = 0.019), perseverative responses (P = 0.041), perseverative errors (P = 0.040), and total errors (P = 0.049) on the WCST compared with placebo. The improvements in the PANSS, SANS, and HAM-D-17 scores were not significantly different between the 2 groups at week 8 for observed case and last-observation-carried-forward (LOCF) analyses. The response rates (LOCF) for the PANSS scores in the WSKY and placebo groups were 55.0% and 35.0%, respectively (P = 0.028), while the SANS scores were 63.3% and 45.0% (P = 0.044) and the HAM-D-17 were 35.0% and 45.0% (P = 0.264). There were no significant between-group differences in scores on the AIMS, RSESE, or TESS.CONCLUSIONS: The results of this study suggest that WSKY added to risperidone significantly improved cognitive function in these patients, as measured by the number of completed categories, perseverative responses, perseverative errors, and total errors on the WCST compared with placebo. The response rates in the WSKY group for the PANSS and SANS scores were significantly higher compared with placebo. All treatments were generally well tolerated.

Effects of Zhuangyang Capsule on Cognition in Patients with Negative Symptoms Dominated Schizophrenia

Effrects of Zhuangyang Capsule Added on Risperidone on Cognition and Social Function in Chronic Schizophrenic Patients

Effects of Zhuangyang Capsules on the Serum Prolactin of Schizophrenic Patients Treated with Risperidone

Effects of Warm‐supplementing Kidney Yang (WSKY) Capsule Added on Risperidone on Cognition in Chronic Schizophrenic Patients: a Randomized, Double‐blind, Placebo‐controlled, Multi‐center Clinical Trial

A comparative study of risperidone combined with Daying tablet to treat negative symptoms in patients with schizophrenia

Effectiveness and Tolerability of Warm-Supplementing Kidney Yang Added to Risperidone in Improving Cognitive Impairment in Patients with Schizophrenia: an 8-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

The Effects of Ccrc on Cognition and Brain Activity in Amci Patients: A Pilot Placebo Controlled Bold Fmri Study

The effects ofDaying tablet add-on risperidone on the quality of life of the patients with Schizophrenia

Efficacy and safety of risperidone combined with Daying tablet in the treatment of schizophrenia

Therapeutic Effects of Cerebrolysin Added to Risperidone in Patients with Schizophrenia Dominated by Negative Symptoms

Tianzhi granule improves cognition and BPSD of vascular dementia: a randomized controlled trial

Effects of Daying tablet add-on risperidone on plasma neurotransmitter of schizophrenia

Xi-Xian-Tong-Shuan Capsule Alleviates Vascular Cognitive Impairment in Chronic Cerebral Hypoperfusion Rats by Promoting White Matter Repair, Reducing Neuronal Loss, and Inhibiting the Expression of Pro-Inflammatory Factors.

Efficacy and safety of a Chinese medicine formula Diankuang Mengxing Decoction combined with antipsychotics in the treatment of schizophrenia: A meta-analysis of randomized controlled trials

Study on Clinical Efficacy of Guizhi-fuling Mixture Combined with Risperidone Tabiets in Treatment of Chronic Schizophrenia

Stigma and Efficacy of Zhizhu Kuanzhong Capsules Versus Doxepin in the Treatment of Refractory Functional Dyspepsia: A Randomized Controlled Trial.

The efficacy of oral Zhizhu Kuanzhong, a Traditional Chinese Medicine, in patients with postprandial distress syndrome.

Clinical Efficacy of Wuling Capsules in Treatment of Elderly Patients with Depression and Mild Cognitive Impairment

A Controlled Study of Wuling Capsule in the Treatment of Patients with Gastroesophageal Reflux Disease Accompanied with Depression

Clinical Investigatijon on Effect of Capsule of Wuling Combined with Citalopram in Treating Senile Depression

A control study on short time using benzhexol impact on cognition function of schizophrenia treated with risperidone